---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-040136"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:41:57.954116+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma oral LNC docetaxel shows tumor reduction comparable to IV in melanoma model

## Summary
- Oral LNC docetaxel reduced tumor volume 63% (high dose) and 57% (low dose) vs 68% for IV docetaxel at Day 14.
- No systemic toxicity observed over 10 days; body weight and hematologic parameters stable.
- Company plans further studies in other tumor models and longer treatment regimens to confirm safety.
- Also plans to evaluate LNC formulations for small oligonucleotide anti-tumor activity.

## SEC filing metadata
- accession: 0001493152-23-040136
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315223040136/0001493152-23-040136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315223040136/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-040136
- JSON: https://secwatch.observer/filing/0001493152-23-040136.json
- Plain text: https://secwatch.observer/filing/0001493152-23-040136.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.